Niels Weinhold

Heidelberg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 176 publications

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Journal: Nature medicine

Published: July 06, 2026

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 08, 2026

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 21, 2026

Interpreting [18F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET/CT sub-study of the Phase 3 GMMG-HD7 trial.

Interpreting [18F]FDG-avid fractures after induction therapy in multiple myeloma: insights from the PET/CT sub-study of the Phase 3 GMMG-HD7 trial.

Journal: European journal of nuclear medicine and molecular imaging

Published: April 20, 2026

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

Journal: Leukemia

Published: December 06, 2025

ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance.

ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance.

Journal: International journal of cancer

Published: October 31, 2025

Unlocking myeloma's spatial world at the micrometer scale.

Unlocking myeloma's spatial world at the micrometer scale.

Journal: Blood

Published: October 09, 2025

Fiber intake associates with increased treatment response in patients with multiple myeloma along with changes in gut microbiome.

Fiber intake associates with increased treatment response in patients with multiple myeloma along with changes in gut microbiome.

Journal: Blood advances

Published: September 30, 2025

Fiber intake associates with increased treatment response in multiple myeloma patients along changes in gut microbiome.

Fiber intake associates with increased treatment response in multiple myeloma patients along changes in gut microbiome.

Journal: Blood advances

Published: September 30, 2025

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Journal: Nature medicine

Published: September 26, 2025

Acquired and Selected: Tracking Antigen Escape during T Cell-Redirecting Therapies in Multiple Myeloma.

Acquired and Selected: Tracking Antigen Escape during T Cell-Redirecting Therapies in Multiple Myeloma.

Journal: Blood cancer discovery

Published: September 13, 2025

Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial.

Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial.

Journal: European journal of nuclear medicine and molecular imaging

Published: August 07, 2025

Showing 1-12 of 176

Last Updated: 09/26/2026